RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pradaxa (drug) (INACTIVE)

A collection of news and information related to Pradaxa (drug) (INACTIVE) published by this site and its partners.

Top Pradaxa (drug) (INACTIVE) Articles see all

Displaying items 1-5
  • No new blood thinner for heart valves yet

    Q: I had a heart valve replacement 12 years ago. I need to take warfarin to avoid blood clots on the valve. I have been reading about the newer blood thinners that don't require regular blood tests. I am tired of so many blood tests. Can I ask my doctor about making a switch?
  • Should I try one of the new blood thinners?

    Q. I have atrial fibrillation and have been taking warfarin to prevent blood clots for 10 years. It has not given me any problems. However, I do hate going to my doctor's office to get my INR blood test every month. I'm wondering whether I should switch...

    FDA approves a drug to reverse anticoagulation

    FDA approves a drug to reverse anticoagulation
    Ever since the drug warfarin was discovered to be a highly effective anti-clotting agent as well as a good rat poison in the early 1950s, it has been the frontline weapon in preventing stroke among those with atrial fibrillation. But its growing use has...

    Cost becomes bigger question in treating heart disease

    Cost becomes bigger question in treating heart disease
    LOS ANGELES (Reuters) - The cost of treating heart disease has become a key factor in decisions by U.S. cardiologists grappling with the nation's No. 1 killer. Record prices for drugs and devices, reduced reimbursement by insurance plans and the...

    New Bristol, Pfizer clot drug saves lives in study

    New Bristol, Pfizer clot drug saves lives in study
    PARIS (Reuters) - An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market. Although Eliquis will...